Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Retained Earnings: 2018-2025

Historic Retained Earnings for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to -$28.0 million.

  • China SXT Pharmaceuticals' Retained Earnings fell 34.76% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.4 million, marking a year-over-year decrease of 34.76%. This contributed to the annual value of -$28.0 million for FY2025, which is 13.37% down from last year.
  • As of FY2025, China SXT Pharmaceuticals' Retained Earnings stood at -$28.0 million, which was down 13.37% from -$24.7 million recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Retained Earnings peaked at -$10.0 million during FY2021, and registered a low of -$28.0 million during FY2025.
  • For the 3-year period, China SXT Pharmaceuticals' Retained Earnings averaged around -$24.8 million, with its median value being -$24.7 million (2024).
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 57.64% in 2022, then grew by 13.37% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Retained Earnings (MRY) stood at -$10.0 million in 2021, then tumbled by 57.64% to -$15.7 million in 2022, then tumbled by 37.77% to -$21.6 million in 2023, then decreased by 14.34% to -$24.7 million in 2024, then dropped by 13.37% to -$28.0 million in 2025.
  • Its last three reported values are -$28.0 million in FY2025, -$24.7 million for FY2024, and -$21.6 million during FY2023.